And Gilead seems to be edging away from its partner.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Patients' expression of CEACAM5 might hold the key to activity after all.
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.